What Happened?
Cambridge, MA-based CoLucid Pharmaceuticals, Inc hired Thomas Mathers as CEO.
About the Company
Colucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company`s investors include Pappas Ventures, Domain Associates, Care Capital, Novo Ventures, Triathalon Medical Ventures, TVM Life Science Management, Auriga Partners and Pearl Street Venture Funds. The company is developing oral lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain by health care professionals.
About the Person
Tom joined CoLucid as Chief Executive Officer in 2011. He has more than twenty two years of executive management experience in the life sciences and medical device industry. Mr. Mathers also serves on the Board of Directors for the Biotechnology Industry Organization (BIO), and as founder and chairman of Déclion Holdings and its affiliates. Prior to CoLucid, Tom served as president and CEO of Peptimmune, Inc.; president and CEO of Cell Based Delivery; vice president and general manager of Cardion AG; vice president of Strategic Development at Genzyme; and management positions at Snowden-Pencer and Pfizer, Inc. rnrn Tom holds several patents and patents pending and earned his BS in Engineering from the United States Military Academy at West Point, where he was a Dean's List student and three-year starter on the football team as a defensive end. From 1988 to 1991 he served as captain in the United States Army and was awarded several medals for his services as an AH-64 Apache helicopter pilot in the Gulf War in the XVIII Airborne Corps.
Info Source
Press Release
Short Profile